Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H., Gulrajani, M., Krantz, F., . . . Woyach, J. A. (2016). The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res.
Citação norma ChicagoHerman, Sarah E. M., et al. "The Bruton’s Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia." Clin Cancer Res 2016.
Citação norma MLAHerman, Sarah E. M., et al. "The Bruton’s Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia." Clin Cancer Res 2016.